147 related articles for article (PubMed ID: 19565370)
1. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations.
Schneider C; Jick SS; Meier CR
Climacteric; 2009 Oct; 12(5):445-53. PubMed ID: 19565370
[TBL] [Abstract][Full Text] [Related]
2. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations.
Schneider C; Jick SS; Meier CR
Climacteric; 2009 Dec; 12(6):514-24. PubMed ID: 19905903
[TBL] [Abstract][Full Text] [Related]
3. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women.
Dinger J; Bardenheuer K; Heinemann K
Climacteric; 2016 Aug; 19(4):349-56. PubMed ID: 27174159
[TBL] [Abstract][Full Text] [Related]
4. Use of dydrogesterone in hormone replacement therapy.
Mueck AO; Seeger H; Bühling KJ
Maturitas; 2009 Dec; 65 Suppl 1():S51-60. PubMed ID: 19836909
[TBL] [Abstract][Full Text] [Related]
5. Postmenopausal hormone replacement therapy: scientific review.
Nelson HD; Humphrey LL; Nygren P; Teutsch SM; Allan JD
JAMA; 2002 Aug; 288(7):872-81. PubMed ID: 12186605
[TBL] [Abstract][Full Text] [Related]
6. The effect of HRT on cerebral haemodynamics and cerebral vasomotor reactivity in post-menopausal women.
Bain CA; Walters MR; Lees KR; Lumsden MA
Hum Reprod; 2004 Oct; 19(10):2411-4. PubMed ID: 15284214
[TBL] [Abstract][Full Text] [Related]
7. Dydrogesterone does not reverse the cardiovascular benefits of percutaneous estradiol.
Kuba VM; Teixeira MA; Meirelles RM; Assumpção CR; Costa OS
Climacteric; 2013 Feb; 16(1):54-61. PubMed ID: 22640483
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy and cardiovascular health in the United States.
Shetty KD; Vogt WB; Bhattacharya J
Med Care; 2009 May; 47(5):600-6. PubMed ID: 19319001
[TBL] [Abstract][Full Text] [Related]
9. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
Mueck AO
Climacteric; 2012 Apr; 15 Suppl 1():11-7. PubMed ID: 22432811
[TBL] [Abstract][Full Text] [Related]
10. Myocardial infarction risk and hormone replacement: differences between products.
de Vries CS; Bromley SE; Farmer RD
Maturitas; 2006 Feb; 53(3):343-50. PubMed ID: 16040209
[TBL] [Abstract][Full Text] [Related]
11. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study.
Stojanovic ND; Kwong P; Byrne DJ; Arnold A; Jagroop IA; Nair D; Press M; Hurel S; Mikhailidis DP; Prelevic GM
Angiology; 2003; 54(4):391-9. PubMed ID: 12934758
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
Cole JA; Norman H; Doherty M; Walker AM
Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the contribution of dydrogesterone to bone turnover changes in postmenopausal women commencing hormone replacement therapy.
Tobias JH; Clarke S; Mitchell K; Robins S; Amer H; Fraser WD
J Clin Endocrinol Metab; 2001 Mar; 86(3):1194-8. PubMed ID: 11238508
[TBL] [Abstract][Full Text] [Related]
14. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens.
Smith NL; Blondon M; Wiggins KL; Harrington LB; van Hylckama Vlieg A; Floyd JS; Hwang M; Bis JC; McKnight B; Rice KM; Lumley T; Rosendaal FR; Heckbert SR; Psaty BM
JAMA Intern Med; 2014 Jan; 174(1):25-31. PubMed ID: 24081194
[TBL] [Abstract][Full Text] [Related]
15. Is postmenopausal hormone replacement therapy suitable after a cardio- or cerebrovascular event?
Windler E; Stute P; Ortmann O; Mueck AO
Arch Gynecol Obstet; 2015 Jan; 291(1):213-7. PubMed ID: 25322975
[TBL] [Abstract][Full Text] [Related]
16. Postmenopausal hormone use in women with acute coronary syndromes.
Parsons E; Newby LK; Bhapkar MV; Alexander KP; White HD; Shah SH; Bushnell CD; Califf RM;
J Womens Health (Larchmt); 2004 Oct; 13(8):863-71. PubMed ID: 15671702
[TBL] [Abstract][Full Text] [Related]
17. Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women.
Angeja BG; Shlipak MG; Go AS; Johnston SC; Frederick PD; Canto JG; Barron HV; Grady D;
J Am Coll Cardiol; 2001 Nov; 38(5):1297-301. PubMed ID: 11691498
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of low-dose 17beta-estradiol plus dydrogesterone on 24-h ambulatory blood pressure in healthy postmenopausal women: a 1-year, randomized, prospective study.
Kaya C; Cengiz SD; Cengiz B; Akgun G
Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():62-7. PubMed ID: 17943541
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone.
Norris LA; Brosnan J; Bonnar J; Conard J; Kluft C; Hellgren M
Thromb Haemost; 2008 Aug; 100(2):253-60. PubMed ID: 18690345
[TBL] [Abstract][Full Text] [Related]
20. Postmenopausal hormone replacement therapy and venous thromboembolism.
Wu O
Gend Med; 2005; 2 Suppl A():S18-27. PubMed ID: 16551553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
